Sierra Oncology Company
Sierra Oncology, Inc., a clinical stage drug development company, is advancing targeted therapeutics for the treatment of patients with unmet medical needs in hematology and oncology. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis and has demonstrated a differentiated therapeutic profile encompassing anemia-related benefits, as well as achieving substantive splenic volume reduction and constitutional symptom control.
Founded Date:
2004
Investor Type:
Undisclosed
Employee Number:
51-100
Investment Stage:
N/A
Funding Status:
IPO
Number Of Exists:
N/A
Technology:
Drug Design
Industry:
Drug Discovery
Headquarters:
Vancouver, British Columbia, Canada